This commentary argues that practitioners of cost-effectiveness analyses should incorporate dynamic drug pricing into formal cost-effectiveness analyses (CEAs). For reasons we discuss, doing so will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback